Recent 8-K filings for LEXX

• February 6, 2026, 6:59 PM ET other material materiality 0.65 negative item 3.01 ◈ Listing & Compliance Notices

  Lexaria Bioscience receives Nasdaq bid price deficiency notice; 180 days to cure

  Received Nasdaq deficiency notice on Feb 4, 2026 for failing to meet $1.00 min bid price (Rule 5550(a)(2)).

• September 29, 2025, 7:59 PM ET other material materiality 0.75 neutral item 1.01item 3.02item 8.01item 9.01

  Lexaria closes $4M registered direct offering of 2.67M shares at $1.50 with warrants at $1.37

  Closed on Sept 29, 2025: gross proceeds of $4.0M from 2,666,667 shares at $1.50 and warrants.

• December 18, 2024, 6:59 PM ET other material materiality 0.60 neutral item 1.0

  Lexaria Bioscience signs ~AUD$5.1M clinical study agreement with Novotech for GLP-1-H24-4 trial

  Effective Dec 2, 2024: Novotech as CRO for DehydraTECH Cannabidiol + GLP-1 agonists in pre- and Type II Diabetes.

• October 2, 2024, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 ◈ executive_change ×3

  Lexaria Bioscience appoints Michael Shankman as CFO, effective Oct 1, 2024

  Michael Shankman, CPA, replaces resigned CFO Nelson Cabatuan; CEO Richard Christopher had been interim principal financial officer.

• September 5, 2024, 7:59 PM ET leadership materiality 0.75 neutral item 5.02item 7.01item 9.01 ◈ executive_change ×2

  Lexaria appoints Richard Christopher as CEO; Bunka transitions to Chairman

  Richard Christopher, 54, appointed CEO effective Aug 31, 2024; he also serves as interim CFO until new CFO is hired.

• July 17, 2024, 7:59 PM ET other material materiality 0.70 positive item 5.02item 7.01item 9.01 ◈ executive_change

  Lexaria animal study interim results: DehydraTECH liraglutide and CBD show weight loss; CFO Cabatuan resigns

  CFO Nelson Cabatuan resigned effective July 15; becomes Chief Strategic Financial Advisor; 150k unvested options expire, vested 50k options reduced to July 2026.

• April 30, 2024, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 3.02item 9.01 ◈ Material Agreements

  Lexaria exercises warrants for ~$4.4M, issues new warrants with $4.75 strike

  Existing investor exercises 2,917,032 warrants for ~$4.4M; gross proceeds ~$4.7M including new warrant consideration.

• March 15, 2024, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 ◈ executive_change

  Lexaria Bioscience appoints Nelson Cabatuan as CFO effective March 14, 2024

  Nelson Cabatuan, age 46, replaces temporary outsourced CFO services from NOW CFO.

• March 1, 2024, 6:59 PM ET other material materiality 0.75 positive item 8.01

  Lexaria Bioscience receives FDA clearance for Phase 1b hypertension trial HYPER-H23-1

  FDA issued 'Study May Proceed' letter on Feb 29, 2024, for Lexaria's Investigational New Drug application.

• February 16, 2024, 6:59 PM ET other material materiality 0.65 neutral item 1.01item 3.02item 8.01item 9.01 ◈ Material Agreements ×2

  Lexaria raises $3.6M in registered direct offering and private placement

  Gross proceeds of ~$3.6M from issuance of 1,558,443 shares at $2.31/share and pre-funded warrants at $2.3099.

• January 30, 2024, 6:59 PM ET regulatory materiality 0.60 neutral item 8.01

  Lexaria files IND with FDA for phase 1b hypertension trial of DehydraTECH-CBD

  Submitted IND to FDA on Jan 29, 2024, for phase 1b trial HYPER-H23-1 in stage 1 or 2 hypertension.

• January 24, 2024, 6:59 PM ET other material materiality 0.70 positive item 7.01item 9.01

  Lexaria CEO provides 2024 outlook; GLP-1 pilot shows DehydraTECH semaglutide benefit; IND filing imminent

  Stock recovered above $1, avoiding reverse split; October capital raise on less punitive terms.

Executive changes

Materiality & sentiment trend

Max materiality 0.75 · Median 0.55 · Most common event other_material

4 positive 2 negative 19 neutral

source · LEXX on sec.gov